Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Wanda Appoints Medical Director

27 Jul 2016 07:00

RNS Number : 3124F
NetScientific PLC
27 July 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Wanda Names Dr. Suzanne Steinbaum, Renowned Cardiologist and Women's Heart Health Advocate, as Medical Director

 

Dr. Steinbaum joins Wanda's mission to create personalized health guidance and accountability using advanced predictive analytics, behavioural science, and mobile technologies.

 

London, UK - 27 July 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, notes Wanda's announcement of the appointment of Dr. Suzanne Steinbaum, a board-certified cardiologist and well-known national advocate for women's heart health, as Medical Director.

 

Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific, said: "Dr. Steinbaum's extensive clinical experience and background in cardiology will make her a valuable addition to Wanda's already distinguished team."

 

The full text of the announcement issued by Wanda on 26 July 2016 is as follows:

 

 

 

Dr. Suzanne Steinbaum, Renowned Cardiologist and Women's Heart Health Advocate, Named Medical Director for Wanda

 

Dr. Steinbaum joins Wanda's mission to create personalized health guidance and accountability using advanced predictive analytics, behavioral science, and mobile technologies.

 

SAN FRANCISCO - July 26, 2016 - Wanda, a leading digital health platform dedicated to advancing the effectiveness and efficiency of patient care, today announced that Dr. Suzanne Steinbaum, board-certified cardiologist and well-known national advocate for women's heart health, has joined the company as Medical Director.

 

Dr. Steinbaum is a Fellow of the American College of Cardiology and a Fellow of the American Heart Association, and has been trained in both Cardiology and Preventative Cardiology. She is also a National Spokesperson for the American Heart Association's Go Red for Women campaign and chairs Go Red for Women in New York City. She will lend her world-class expertise and leadership to further Wanda's mission of empowering users to improve their own health through data-driven insights and personalized guidance.

 

"We're thrilled to have Dr. Steinbaum join our distinguished team of data scientists, engineers, and designers to help us focus on tackling mankind's number one killer: heart disease," said Wanda's CEO Steve Curd. "Dr. Steinbaum adds an invaluable amount of clinical competence and a deep understanding of what it takes to keep people at risk of heart disease out of the hospital."

 

Wanda's digital health platform collects critical information from individuals and utilizes machine learning to deliver ongoing risk analysis and decision support. Combined with a smart, inspirational, and engaging interface, Wanda's capabilities enable users to better manage their own cardiovascular health. The result is not only a higher quality of life, but a significant reduction in the cost burden of these individuals.

 

"Wanda is at the forefront of a critical turning point in healthcare, in which patient engagement is essential to successful outcomes," said Dr. Steinbaum. "I have devoted my entire career to the treatment of heart disease through early detection, education, and prevention. The moment I met the Wanda team, I realized our collaboration could provide an incredibly unique force in preventing our country's number one killer. While heart disease is 80 to 90% preventable, lifestyle changes are critical, and this is where Wanda comes in. Wanda's ability to monitor health markers and personalize recommendations to create impactful changes for the individual will ultimately change outcomes."

 

Despite the fact that over 50% of heart-related hospitalizations are avoidable, heart disease remains one of America's most expensive health challenges. Until now, no one has brought together all of the pieces necessary to impact this immense problem at scale, which drives an estimated $100 billion of cost in the US alone.

 

"Instead of treating people as 'passive data sources' to be tested, examined, treated, and often criticized for non-compliance, we believe that the only effective approach is to engage each individual in a meaningful dialog to personalize the experience," says Mark Heinemeyer, CCO for Wanda. "As we learn more about each individual, we can guide them to make more intelligent, accountable decisions affecting their hearts."

 

 

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

 

About Wanda

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found at www.yourwanda.com.

 

About Dr. Suzanne Steinbaum

Dr. Suzanne Steinbaum is an attending cardiologist and the Director of Women's Heart Health of Lenox Hill Hospital in New York City. She has done fellowship training in both Preventive Cardiology and Cardiology. She recently released her book Dr. Suzanne Steinbaum's Heart Book: Every Woman's Guide to a Heart Healthy Life, teaching all women how to lead the healthiest lives by living from the heart. She is the host of Focus onHealth, a weekly magazine news show spotlighting health topics, seen on WLNYTV. She has been awarded a New York Times Super Doctor, and a Castle and Connolly Top Doctor for Cardiovascular Disease.

 

Dr. Steinbaum is a Fellow of the American College of Cardiology and a Fellow of the American Heart Asssociation in Epidemiology and Prevention. She is a National Spokesperson for the Go Red for Women campaign and chairperson of Go Red for Women in New York City.

 

Dr. Steinbaum has devoted her career to the treatment of heart disease through early detection, education, and prevention. She has lectured nationally on topics of coronary artery disease, women and heart disease, natural and alternative ways of treating heart disease and the prevention of heart disease. She is often cited in magazines and newspapers and is regularly seen on network news health segments for ABC, NBC and CBS, CNN, WPIX and FOX as a leading consultant in the field of women and heart disease, preventive cardiology and topics of lifestyle management. She is regularly interviewed for breaking news in U.S. News and World Report, Healthday and WebMD. She has written on topics of cardiac prevention and nutrition and has been quoted in many publications and magazines, such as Self, Glamour, More, Fitness, The Wall Street Journal and Family Circle. She is a regular contributor to The Huffington Post, Dr. Oz, Bottomline Health, and Sharecare.

 

Her unique perspectives on health, wellness and overall vitality by living a heart-centered life can be found at www.srsheart.com, on Facebook at Dr. Suzanne Steinbaum and Twitter at @DrSteinbaum.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPGUMUMUPQGQQ
Date   Source Headline
16th Sep 20242:31 pmRNSPDS: Updated Results, VERSATILE-002 Phase 2 Trial
13th Aug 20243:57 pmRNSPDS Biotech: Business Update and Q2 2024 Results
2nd Aug 202412:21 pmRNSReplacement RNS: PDS Biotech Aligns with FDA
2nd Aug 20247:00 amRNSPDS Biotech Aligns with FDA on Phase 3 Trial
30th Jul 20247:00 amRNSQ-Bot Fundraising
10th Jul 202410:48 amRNSResult of AGM
18th Jun 20247:00 amRNSNotice of AGM
14th Jun 20242:10 pmRNSTR-1
14th Jun 20247:00 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSPreliminary Results for the year ended 31 Dec 2023
31st May 20247:01 amRNSNotice of Results and Investor Presentation
31st May 20247:00 amRNSDeepTech Recycling: Fundraising, Business Update
28th May 20247:00 amRNSInvestment in Wanda, related party transactions
15th May 20242:32 pmRNSPDS Biotech: Business Update and Q1 2024 Results
13th May 20247:00 amRNSMartlet Capital: mandate and acquisition
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.